NCT07366099 2026-01-26
Al18F-NOTA-LM3 PET/CT in Patients With TIO
Peking Union Medical College Hospital
Phase NA Recruiting
Clinical Trials
11 trialsNCT04783428 2026-01-21
Tumor-induced Osteomalacia Disease Monitoring Program
Ultragenyx Pharmaceutical Inc
Active not recruiting
NCT03775187 2025-03-05
Expanded Access to Burosumab
Kyowa Kirin Co., Ltd.
Available
NCT05357573 2024-07-09
Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With TIO
Kyowa Kirin Co., Ltd.
Phase 4 Completed
NCT02304367 2024-05-06
Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)
Kyowa Kirin Co., Ltd.
Phase 2 Completed
NCT02722798 2022-09-06
A Study of KRN23 in Subjects With Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome
Kyowa Kirin Co., Ltd.
Phase 2 Completed
NCT03510455 2021-04-08
BGJ398 for the Treatment of Tumor-Induced Osteomalacia
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT04689893 2021-01-05
Application of 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT in the Diagnosis and Evaluation of TIO
Peking Union Medical College Hospital
Phase 1 Unknown
NCT01748812 2018-07-05
Cinacalcet for Fibroblast Growth Factor 23 (FGF23)-Mediated Hypophosphatemia (Hypophosphatemic Rickets)
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT00099762 2017-07-02
Catheterization to Locate Mesenchymal Tumors in Patients With Tumor-Induced Osteomalacia or Oncogenic Osteomalacia
National Institutes of Health Clinical Center (CC)
Completed
NCT01524016 2017-04-07
68Ga-DOTATATE PET/CT in Oncogenic Osteomalacia
Peking Union Medical College Hospital
Phase EARLY_PHASE1 Unknown